Irrinus Fonyuy Kintung

Mr. Irrinus Fonyuy Kintung

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NNNiels Kaze NGUEDIA
Niels Kaze NGUEDIA
EAEmmanuel Chimuebuka Amadi
Emmanuel Chimuebuka Amadi
Irrinus Fonyuy KintungIrrinus Fonyuy Kintung
Irrinus Fonyuy Kintung
Olubanke OgunlanaOlubanke Ogunlana
Olubanke Ogunlana
Shalom ChineduShalom Chinedu
Shalom Chinedu
Prostate cancer is a major cause of cancer-related deaths among men in Sub-Saharan Africa, where late-stage diagnoses are common due to limited access to affordable and sensitive diagnostic tools. Early detection is essential to improve survival and reduce the disease burden. This review explores the integration of epigenetic biomarkers and CRISPR-Cas12a technology as a transformative approach for early, non-invasive prostate cancer detection in resource-limited settings. Among the many complexities of cancer development, molecular dysregulation plays a remarkable role, and epigenetic modifications such as DNA methylation, histone changes, and non-coding RNA expression have emerged as stable and specific biomarkers with significant potential for the early detection and characterisation of prostate carcinogenesis. However, their low concentration in body fluids presents a detection challenge. CRISPR-Cas12a, known for its high specificity and sensitivity, offers a promising solution. When combined with isothermal amplification and liquid biopsy techniques, it enables rapid, low-cost, and point-of-care diagnostics. This review proposes a low-cost, CRISPR-Cas12a-based diagnostic pipeline for detecting prostate cancer-specific epigenetic markers in liquid biopsies. The implementation of this technology in Sub-Saharan Africa could significantly improve early diagnosis, reduce mortality, and advance health equity.